|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
A novel coronavirus disease 2019 (COVID-19) outbreak is a global dramatic pandemic that is immeasurably impacting the communities. Due to lack of data, symptomatic management is used for COVID-19 infection including oxygen therapy and mechanical ventilation for those with severe infection. Considering immunomodulatory, anti-inflammatory anti-fibrotic and anti-oxidant actions of vitamin D, it's safety and ease of administration, as well as direct effects of vitamin D on immune cell proliferation and activity, pulmonary ACE2 expression and reducing surface tension, evaluation of vitamin D supplementation as an adjuvant therapeutic intervention could be of substantial clinical and economic significance. High prevalence of vitamin D deficiency in elderly, smokers, patients with chronic diseases and excess uptake by adipose tissue in obesity make investigations of its role as a secondary therapeutic agent in COVID-19 conceivable. It should be necessary to monitor serum 25(OH)D levels in all inpatient and outpatient populations with COVID-19 to identify the importance of maintaining or promptly increasing circulating levels of 25(OH)D into the optimal range of 100-150 nmol/L. The aim of this study is to conduct a double blind, randomized, controlled three weeks clinical trial on the efficacy of vitamin D (daily low dose versus weekly high dose) in COVID-19 patients in order to determine the relationship between baseline vitamin D deficiency and clinical characteristics and to asses patients' response to vitamin D supplementation in week three and determine its association with disease progression and recovery. Subjects who are randomized to high-dose will be asked to take 50,000 IU for two times during the first week and one dose over second and third weeks to quickly raise their serum levels. Subjects in the low-dose arm will take vitamin D 1000 IU daily for three weeks.
Description: Number of Participants whose symptoms recovered over three weeksMeasure: Symptoms recovery Time: Time from onset of intervention to day 21
Description: Number of patients who required hospitalizationMeasure: Hospitalization Time: Between diagnosis and day 21
Description: x 109/LMeasure: Blood white blood cell count (WBC) Time: At day 0 before starting intervention and day 21 of intervention
Description: If patients required mechanical ventilation at any time after diagnosisMeasure: Duration of mechanical ventilation Time: Between diagnosis and day 21
Description: Length of stay in hospital (days)Measure: Duration of hospitalization Time: Between diagnosis and day 21
Description: Number of patients who required ICUMeasure: Intensive care unit (ICU) admission Time: Between diagnosis and day 21
Description: Length of stay in ICUMeasure: Duration of ICU stay Time: Between diagnosis and day 21
Description: mg/LMeasure: Blood C-reactive protein (CRP) Time: Baseline and day 21
Description: number of lymphocytes in 1 microliter (µL) of bloodMeasure: Blood Lymphocyte count Time: Baseline and day 21
Description: ng/mLMeasure: Blood Ferritin Time: Baseline and day 21
Description: platelets per microliter of bloodMeasure: Blood platelet count Time: Baseline and day 21
Description: pg/mLMeasure: Blood interleukin-6 (IL-6) Time: Baseline and day 21
Description: pg/mlMeasure: Blood Tumor Necrosis Factor alpha (TNF) Time: Baseline and day 21
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports